Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by equities researchers at BidaskClub from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.
A number of other brokerages also recently issued reports on SRPT. Bank of America decreased their price target on Sarepta Therapeutics from $190.00 to $189.00 and set a "buy" rating for the company in a report on Friday, August 21st. Raymond James started coverage on Sarepta Therapeutics in a research note on Monday, August 24th. They set an "outperform" rating and a $200.00 target price for the company. JPMorgan Chase & Co. upped their target price on Sarepta Therapeutics from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, June 22nd. Citigroup upped their target price on Sarepta Therapeutics from $177.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Credit Suisse Group downgraded Sarepta Therapeutics from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $185.00 to $167.00 in a research note on Thursday, August 20th. Two analysts have rated the stock with a sell rating, two have given a hold rating and twenty-three have given a buy rating to the company. The company currently has a consensus rating of "Buy" and a consensus price target of $194.79.
Sarepta Therapeutics stock opened at $142.80 on Wednesday. Sarepta Therapeutics has a 52 week low of $72.05 and a 52 week high of $175.00. The company has a market capitalization of $11.21 billion, a price-to-earnings ratio of -20.34 and a beta of 1.84. The stock has a 50-day moving average price of $147.45 and a 200 day moving average price of $136.96. The company has a quick ratio of 6.42, a current ratio of 6.93 and a debt-to-equity ratio of 0.67.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($1.93) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.73) by ($0.20). Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. The company had revenue of $137.36 million during the quarter, compared to analyst estimates of $112.36 million. Research analysts anticipate that Sarepta Therapeutics will post -7.28 EPS for the current fiscal year.
In other Sarepta Therapeutics news, EVP David T. Howton sold 105,122 shares of the company's stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $170.88, for a total value of $17,963,247.36. Following the completion of the sale, the executive vice president now directly owns 33,151 shares in the company, valued at approximately $5,664,842.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Joseph Bratica sold 1,125 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $155.00, for a total value of $174,375.00. Following the completion of the sale, the insider now owns 8,957 shares of the company's stock, valued at $1,388,335. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,247 shares of company stock valued at $24,482,622. 5.90% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the business. Private Advisor Group LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter valued at $30,000. Ameritas Investment Company LLC purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $28,000. NWK Group Inc. grew its holdings in shares of Sarepta Therapeutics by 30.0% during the 1st quarter. NWK Group Inc. now owns 325 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 75 shares during the period. Schroder Investment Management Group purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $38,000. Finally, CSat Investment Advisory L.P. grew its holdings in shares of Sarepta Therapeutics by 19.7% during the 1st quarter. CSat Investment Advisory L.P. now owns 571 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 94 shares during the period. Institutional investors own 92.70% of the company's stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Story: How to calculate the annual rate of depreciation
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
12 Marijuana Stocks to Buy Now
There are now more than 50 publicly-traded companies operating in the cannabis industry. Most of these companies aren't directly growing and selling marijuana themselves, but they do stand to benefit greatly as more states legalize the sale and possession of marijuana. Some of these marijuana stocks are media companies. Others are privately studying the medical uses of marijuana. Yet others are providing tools and software for marijuana growers. As more cannabis companies file IPOs and enter the stock market, it will become increasingly difficult for investors to identify which marijuana stocks will truly benefit from the cannabis boom.
Our subscribers have begun digging through these companies, checking out their financials, business models and long-term growth prospects. They know that some "marijuana stocks" are just empty shell companies that deserve to be penny stocks, but they also recognize there are some legitimate and growing companies that truly stand to benefit from the green rush. As a group, they have added 10 different cannabis stocks to their watchlists and are actively investing in them. More than 1,400 MarketBeat subscribers are now following our top-trending cannabis company.
This slide show lists the 12 pot stocks that MarketBeat subscribers are have added to their watchlists and are actively monitoring.
View the "12 Marijuana Stocks to Buy Now".